| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:29Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-03-05T06:07:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; MING-CHU CHANG; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-04T07:50:46Z |
Inhibiting autophagy potentiates the antitumor efficacy of Euphorbia royleana for canine mammary gland tumors
|
Huang, Y.-Y.;Chen, C.-H.;Hsu, C.-H.;Kuo, T.-Y.;Liu, C.-C.;Liao, A.T.-C.;Liao, A.T.-C.;Lin, C.-S.;Lin, C.-S.; Huang, Y.-Y.; Chen, C.-H.; Hsu, C.-H.; Kuo, T.-Y.; Liu, C.-C.; Liao, A.T.-C.; Liao, A.T.-C.; Lin, C.-S.; Lin, C.-S.; CHEN-SI LIN |
| 臺大學術典藏 |
2021-03-04T02:36:03Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.;Yeh K.-H.;Yang C.-H.;Hsu C.;Yu-Chieh Tsai;Hsu W.-L.;Cheng A.-L.;Hsu C.-H.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; YU-CHIEH TSAI; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; YU-CHIEH TSAI; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Hsu F.-M.; Lin C.-C.; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; YU-CHIEH TSAI; Lee Y.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy
|
Hsu F.-M.; Lee Y.-C.; Lee J.-M.; Hsu C.-H.; Lin C.-C.; YU-CHIEH TSAI; Wu J.-K.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:00Z |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma
|
Hsu F.-M.;Lee J.-M.;Huang P.-M.;Lin C.-C.;Hsu C.-H.;Yu-Chieh Tsai;Lee Y.-C.;Chia-Hsien Cheng J.; Hsu F.-M.; Lee J.-M.; Huang P.-M.; Lin C.-C.; Hsu C.-H.; YU-CHIEH TSAI; Lee Y.-C.; Chia-Hsien Cheng J. |
| 臺大學術典藏 |
2021-03-04T02:35:58Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; YU-CHIEH TSAI; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-03-04T02:35:57Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; YU-CHIEH TSAI; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-03-04T02:35:55Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Cheng J.C.-H.;Huang C.-Y.;Yu-Chieh Tsai;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Pu Y.-S.; Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; YU-CHIEH TSAI; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Yu-Yun Shao;Hsu C.;Hsu C.-H.;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
Solving the deficit of cancer pain management skills by education programs
|
YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-02-25T07:00:57Z |
It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
|
Liu T.-H.; YU-YUN SHAO; Hsu C.-H. |
| 臺大學術典藏 |
2021-02-25T07:00:57Z |
Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma
|
Wu C.-H.; Liang P.-C.; Hsu C.-H.; Chang F.-T.; YU-YUN SHAO; Ting-Fang Shih T. |
| 臺大學術典藏 |
2021-02-23T08:26:44Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Sung-Hsin Kuo;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; SUNG-HSIN KUO; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:42Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Sung-Hsin Kuo;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; SUNG-HSIN KUO; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:41Z |
A pathway for tumor necrosis factor-�\-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-�eB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus
|
Pei Y.Y.; SUNG-HSIN KUO; Yeh K.-H.; Chuang S.-E.; Hsu C.-H.; Wen C.C.; Lin H.-I.; Gao M.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:36Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Sung-Hsin Kuo;Hsu C.;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Sung-Hsin Kuo;Hsu C.-H.;Chen L.-T.;Lu Y.-S.;Lin C.-H.;Yeh P.-Y.;Jeng H.-J.;Gao M.;Yeh K.-H.;Cheng A.-L.; SUNG-HSIN KUO; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.;Yeh P.-Y.;Gao M.;Chen C.-W.;Yeh L.-C.;Feng W.-C.;Sung-Hsin Kuo;Hsu C.-H.;Lu Y.-S.;Cheng A.-L.; Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO; Hsu C.-H.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:32Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Hsu C.-H. ;Sung-Hsin Kuo ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:32Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Sung-Hsin Kuo ;Cheng A.-L. ;Lin C.-W. ;Hsu C.-H. ;Wu M.-S. ;Yeh K.-H. ;Tzeng Y.-S. ;Chen L.-T.; SUNG-HSIN KUO; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-23T08:26:28Z |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-�eb is associated with a poor prognosis of pancreatic cancer
|
Yang S.-H.;Hsu C.-H.;Lee J.-C.;Tien Y.-W.;Sung-Hsin Kuo;Cheng A.-L.; Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:21Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-04T02:30:20Z |
The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer
|
Sun, Y.-J.;Hsu, C.-H.;Ling, T.-Y.;Liu, L.;Lin, T.-C.;Jakfar, S.;Young, I.-C.;Lin, F.-H.Feng-Huei Lin; Sun, Y.-J.; Hsu, C.-H.; Ling, T.-Y.; Liu, L.; Lin, T.-C.; Jakfar, S.; Young, I.-C.; Lin, F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2021-02-04T02:29:43Z |
Process integration of E-waste carbonization and High-gravity rotating packed bed for optimal gold recovery and the fine particles reduction
|
Huynh, G.-H.;Chen, T.-L.;Hsu, C.-H.;Chen, Y.-H.;Chiang, P.-C.; Huynh, G.-H.; Chen, T.-L.; Hsu, C.-H.; Chen, Y.-H.; Chiang, P.-C.; PEN-CHI CHIANG |
| 臺大學術典藏 |
2021-02-03T05:42:26Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
CHIA-HUNG TU; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; Lee Y.-C. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T05:45:47Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
Tu C.-H.;Lee C.-T.;Perng D.-S.;Chang C.-C.;Hsu C.-H.;Yi-Chia Lee; Tu C.-H.; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; YI-CHIA LEE |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:42Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; MING-SHIANG WU; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.;Hsu C.-H.;Chen J.;Tsai T.-C.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.;Chen J.;Wu C.-Y.;Cheng A.-L.;Yeong-Shiau Pu; Hsu C.-H.; Chen J.; Wu C.-Y.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Chen J.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Lin C.-C.;Hsu C.-H.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:59Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Huang K.-H.;Chen J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
